Payment overview · 2025
General Payments
$382.12
17 reported records · 10 companies
Healthcare provider profile · identity verified
Andrew Hein, DO
Allopathic & Osteopathic Physicians|Family Medicine · TAMPA, FL · NPI 1609004902
Verified facts
What the public records show
CMS Open Payments records show Andrew Hein, DO received $382.12 in general payments during 2025 across 17 reported records.
Dexcom, Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $78.34 | 20.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.50 | 16.4% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $49.85 | 13.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.52 | 11.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.47 | 8.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.40 | 7.7% | 2 | 2025 |
| McKesson Medical-Surgical, Inc. | Unresolved — no canonical attribution shown | $28.22 | 7.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.26 | 6.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.79 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.77 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.12 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.50 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $49.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.52 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
132 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 125 |
| Metformin Hcl | Metformin Hcl | 205 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 76 |
| Lisinopril | Lisinopril | 198 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 57 |
| Montelukast Sodium | Montelukast Sodium | 174 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 65 |
| Losartan Potassium | Losartan Potassium | 155 | 54 |
| Furosemide | Furosemide | 135 | 48 |
| Farxiga | Dapagliflozin Propanediol | 132 | 42 |
| Gabapentin | Gabapentin | 129 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 45 |
| Celecoxib | Celecoxib | 112 | 42 |
| Carvedilol | Carvedilol | 111 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 35 |
| Tramadol Hcl | Tramadol Hcl | 96 | 30 |
| Eliquis | Apixaban | 90 | 30 |
| Omeprazole | Omeprazole | 88 | 30 |
| Alendronate Sodium | Alendronate Sodium | 84 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 33 |
| Jardiance | Empagliflozin | 77 | 31 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 23 |
| Prednisone | Prednisone | 68 | 34 |
| Januvia | Sitagliptin Phosphate | 66 | 20 |
| Baclofen | Baclofen | 62 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 18 |
| Trazodone Hcl | Trazodone Hcl | 48 | 25 |
| Famotidine | Famotidine | 47 | 18 |
| Ezetimibe | Ezetimibe | 45 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 18 |
| Potassium Chloride | Potassium Chloride | 38 | 15 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | 16 |
| Finasteride | Finasteride | 34 | 13 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 13 |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Allopurinol | Allopurinol | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Sertraline Hcl | Sertraline Hcl | 22 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.12 · 17 records | Dexcom, Inc. | AIRSUPRA, AREXVY, CAPVAXIVE, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, LEQVIO, MOUNJARO, PENMENVY, QUTENZA, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error